Advanced search
Publication Cover
Cancer Investigation Volume 39, 2021 - Issue 9
Submit an article Journal homepage
185
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients

Nadia ElMenshawya Clinical Pathology Department, Hematology Unit, Mansoura Medical School, Mansoura University, Mansoura, EgyptView further author information
,
Nora A. Faraga Clinical Pathology Department, Hematology Unit, Mansoura Medical School, Mansoura University, Mansoura, EgyptView further author information
,
Doaa M. Atiaa Clinical Pathology Department, Hematology Unit, Mansoura Medical School, Mansoura University, Mansoura, EgyptView further author information
,
Nashwa Abousamraa Clinical Pathology Department, Hematology Unit, Mansoura Medical School, Mansoura University, Mansoura, EgyptView further author information
,
Doaa Shahina Clinical Pathology Department, Hematology Unit, Mansoura Medical School, Mansoura University, Mansoura, EgyptView further author information
,
Eman Fawzia Clinical Pathology Department, Hematology Unit, Mansoura Medical School, Mansoura University, Mansoura, EgyptView further author information
,
Hayam Ghazib Department of Medical Oncology, Mansoura Oncology Center, Mansoura University, Mansoura, EgyptView further author information
,
Attalla F. El-kottc Department of Biology, College of Science, King Khalid University, Saudi Arabia;d Department of Zoology, Faculty of Science, Damanhour University, Damanhour, EgyptView further author information
&
Mohamed Eissae Pathology Department, College of Medicine, King Khalid University, Abha, KSA;f Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, EgyptCorrespondence[email protected]
View further author information
 show all
Pages 777-782 | Received 26 Jan 2021, Accepted 01 Aug 2021, Published online: 25 Aug 2021

References

  • Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, et al. High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment. J Clin Med. 2019;8(7):997.
  • Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37. doi:https://doi.org/10.1007/s40265-017-0841-y.
  • Harding T, Baughn L, Kumar S, Van Ness B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia. 2019;33(4):863–883. doi:https://doi.org/10.1038/s41375-018-0362-z.
  • Martín P, Gómez M, Lamana A, Cruz-Adalia A, Ramírez-Huesca M, Ursa MA, et al. CD69 association with Jak3/Stat5 proteins regulates Th17 cell differentiation. Mol Cell Biol. 2010;30(20):4877–4889. doi:https://doi.org/10.1128/MCB.00456-10.
  • Cibrián D, Sánchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47(6):946–953. doi:https://doi.org/10.1002/eji.201646837.
  • Buda G, Carulli G, Orciuolo E, Sammuri P, Campa D, Galimberti S, Petrini M. CD69, a new potential clinical marker in multiple myeloma. Blood. 2014;124(21):2027.
  • Skerget M, Skopec B, Zadnik V, Zontar D, Podgornik H, Rebersek K, et al. CD56 expression is an important prognostic factor in multiple myeloma even with Bortezomib Induction. Acta Haematol. 2018;139(4):228–234.
  • Mace EM, Gunesch JT, Dixon A, Orange JS. Human NK cell development requires CD56-mediated motility and formation of the developmental synapse. Nat Commun. 2016;7:12171.
  • Deneka AY, Boumber Y, Beck T, Golemis EA. Tumor-targeted drug conjugates as an emerging novel therapeutic approach in small cell lung cancer (SCLC). Cancers. 2019;11(9):1297.
  • Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016;36(36):e418–e423.
  • Chen-Kiang S. Cell-cycle control of plasma cell differentiation and tumorigenesis. Immunol Rev. 2003;194:39–47.
  • Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265.
  • Sun CY, Li JY, Chu ZB, Zhang L, Chen L, Hu Y. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis. Biosci Rep. 2017;37(4).
  • Sahara N, Takeshita A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma. 2004;45(1):61–65.
  • Iriyama N, Miura K, Hatta Y, Kobayashi S, Uchino Y, Kurita D, et al. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017;13(5):3803–3808.
  • Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The evolution of prognostic factors in multiple myeloma. Adv Hematol. 2017;2017:4812637.
  • Ceran F, Falay M, Dağdaş S, Özet G. The assessment of CD56 and CD117 expressions at the time of the diagnosis in multiple myeloma patients. Turk J Haematol. 2017;34:226–232.
  • Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, et al. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. PLOS One. 2018;13(5):e0196780.
  • Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013;12(6):1140–1150.
  • Ziogas DC, Dimopoulos MA, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies. Expert Rev Hematol. 2018;11(11):863–879.
  • Khalaf WS, Garg M, Mohamed YS, Stover CM, Browning MJ. In vitro generation of cytotoxic T cells with potential for adoptive tumor immunotherapy of multiple myeloma. Front Immunol. 2019;10:1792.
  • Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012;97(9):1348–1356.
  • Chawla DS. Immunotherapies target multiple myeloma. Nature. 2020;587:S66–S67.
  • Pazina T, MacFarlane AW, 4th, Bernabei L, et al. Alterations of NK cell phenotype in the disease course of multiple myeloma. Cancers. 2021;13(2):226. doi:https://doi.org/10.3390/cancers13020226.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.